Where AR & VR Are Headed In Life Sciences Industry?
BioSpectrum Asia|March 2020
The rise of MedTech is transforming the healthcare industry, as augmented reality (AR) and virtual reality (VR) have pushed the right buttons with players by offering high-tech solutions to fix prevailing challenges in medical training, diagnostics, and treatments. The development of state-of-the-art technologies such as digital reality has disrupted the industrial scenario, and tools such as AR and VR have gained immense popularity in one stroke. Yet, the industrial adoption of digital reality remained significantly low since its inception, and the application range was fairly narrow due to low penetration and high cost of AR and VR tools.
Where AR & VR Are Headed In Life Sciences Industry?

The unprecedented growth of the electronics and telecommunications industry marks this decade as the golden period for advancements in technology. Next-generation technologies have given modern electronic appliances advanced processing controls, which enable end-users to experience the new aspects of the real world.

Hearteningly, though, the technology has witnessed widespread implementation in the recent years. In 2017, the global market for virtual reality accounted for nearly $ 3 billion, and the valuation is set to grow at least twice as large by 2022. Now, augmented reality (AR) and virtual reality (VR) tools are taking over efficiency- and testing-related tasks in a widening range of industrial applications.

Seeing is believing’

Despite the advent of many groundbreaking inventions and medical discoveries, the healthcare industry is still grappling to find a cure for many deadly diseases. As there is no loss costlier than the loss of a human life, healthcare industry has begun to invest in AR and VR driven simulation tools to discover new and efficient ways to save more lives.

Healthcare industry is one of the very first and very few industries to embrace digital reality on a significantly large scale. In 2018, the adoption of medical devices integrated with AR and VR technologies in the healthcare industry generated a revenue of $ 600 million. Taking into consideration the rate at which the penetration of digital reality is increasing in this landscape, the global market for AR and VR in healthcare is expected to reach a valuation of more than $ 15 billion by 2026. The healthcare AR and VR market is set to witness unprecedented growth at an astonishing CAGR (compound annual growth rate) of nearly 49 per cent between 2018 and 2026.

This story is from the March 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the March 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024